The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2021. This month is one technology appraisal that impacts upon primary care.
The Dapagliflozin for treating chronic heart failure with reduced ejection fraction technology appraisal has been published. This treatment is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
- angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
- sacubitril valsartan, with beta blockers and, if tolerated, MRAs
It is also noted that this treatment should only be started on the advice of a heart failure specialist.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - February 2021||CKS Updates - February 2021 »|